Randomized comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709–713.
, , , , , , , .
Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry 1995; 58: 44–50.
, , , , , , .
Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case-control study. British Journal of Obstetrics and Gynaecology 2008; 115: 98–103.
, , , , , , .
, , , , , , , , , . Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures
. New England Journal of Medicine 1985
Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008; 70: 1586–1593.
, , , , .
Antiepileptic drugs – Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239–1276.
, , , , , , , , .
The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365–385.
, , , .
Clinically important interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurology 2003; 2: 347–356.
Clinically important interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurology 2003; 2: 473–481.
Chronic antiepileptic drug toxicity: a review. Epilepsia 1975; 16: 319–352.
Prevalence and risk factors for vitamin D insufficiency among children with epilepsy. Pediatric Neurology 2010; 42: 422–426.
, , .